Kamada Completes Phase II Cystic Fibrosis Trial
Kamada has completed a Phase II study with aerosolized alpha-1 antitrypsin, delivered via an optimized eFlow platform nebulizer from PARI Pharma, in cystic fibrosis.
The trial aimed at validating the safety of the product in cystic fibrosis patients and to assess its potential influence on lung inflammation.
Preliminary results indicate that the product has an excellent safety profile; final data should be available by year-end 2008, said Kamada.
The trial, which was a double-blind, placebo-controlled study was performed at the Cystic Fibrosis Medical Center – Hadassah – Hebrew University Medical Center Mount Scopus in Jerusalem, Israel.
David Tsur, CEO of Kamada, said: “This is a major milestone for Kamada. There is significant potential for the aerosolized version of aerosolized alpha-1 antitrypsin, which is an innovative approach for treatment of chronic inflammatory processes that could potentially prevent degeneration of lung function.”